# US 2025/0320307 A1 · Anti-4-1bb nanobodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0320307 A1
- Document ID: US20250320307A1
- Status: Published application
- Kind: A1
- Application number: 19/197,775
- Filed: 2025-05-02
- Published: 2025-10-16
- Earliest claimed: 2021-08-31
- Assignees: LaNova Medicines Limited Company
- Applicants: Lanova Medicines Limited
- Inventors: Runsheng Li; Wentao Huang
- Web page: https://patentgrep.com/patent/US20250320307A1

## CPC

- A61P 35/00: Antineoplastic agents
- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- C07K 16/30: from tumour cells
- C07K 2317/22: from camelids, e.g. camel, llama or dromedary
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C07K 2317/75: Agonist effect on antigen
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Provided are anti-4-1BB nanobodies and bispecific or multispecific antibodies that incorporate the nanobodies. Methods of using the antibodies for treating and diagnosing diseases such as cancer are also provided.

## Claims

### Claim 1

A single domain antibody or a polypeptide comprising the single domain antibody, wherein the single domain antibody has binding specificity to the human 4-1BB protein and comprises a complementarity determining region 1 (CDR1), a CDR2 and a CDR3, wherein the CDR1 comprises the amino acid sequence of SEQ ID NO: 18, the CDR2 comprises the amino acid sequence of SEQ ID NO:58, and the CDR3 comprises the amino acid sequence of SEQ ID NO:32.

### Claim 2 (depends on 1)

The antibody or polypeptide of claim 1, which comprises the amino acid sequence of any one of SEQ ID NO:40-48 and 60-62.

### Claim 3 (depends on 1)

The antibody or polypeptide of claim 1, which comprises the amino acid sequence of SEQ ID NO: 60.

### Claim 4 (depends on 1)

The antibody or polypeptide of claim 1, wherein the polypeptide is a chimeric antigen receptor (CAR) or a bispecific antibody having a binding specificity to an antigen different from 4-1BB.

### Claim 5 (depends on 1)

A bispecific antibody comprising the antibody of claim 1 and a second antibody or antigen-binding fragment having binding specificity to a target antigen that is not 4-1BB.

### Claim 6 (depends on 1)

One or more polynucleotide(s) encoding the antibody or polypeptide of claim 1.

### Claim 7 (depends on 6)

A cell comprising the polynucleotide of claim 6.

### Claim 8 (depends on 1)

A composition comprising the antibody or polypeptide of claim 1 and a pharmaceutically acceptable carrier.

### Claim 9 (depends on 1)

A method of treating cancer in a patient in need thereof, comprising administering to the patient an effective amount of the antibody or polypeptide of claim 1.
